SCHEMBL6546015

SCHEMBL6546015

Nc1ccc(NC(=O)C=Cc2ccc(-c3ccc([N+](=O)[O-])cc3)o2)cc1C(=O)c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.52
KMT2A Q03164 12/20 0.52
ALDH1A1 P00352 5/20 0.52
RAB9A P51151 2/20 0.52
ALOX12 P18054 1/20 0.52
KDM4E B2RXH2 4/20 0.47
RECQL P46063 3/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 10/20 0.47
DUSP3 P51452 1/20 0.46
NPC1 O15118 3/20 0.45
HTT P42858 3/20 0.44
HPGD P15428 4/20 0.43
POLB P06746 1/20 0.43
DNMT1 P26358 1/20 0.43
MCL1 Q07820 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 1/20 0.43
LMNA P02545 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7052138 1.00 MEN1 (0.52) MEN1KMT2AALDH1A1RAB9AALOX12
SCHEMBL7048231 0.87 MEN1 (0.46) MEN1KMT2AALDH1A1RAB9AALOX12
SCHEMBL6546494 0.87 MEN1 (0.46) MEN1KMT2AALDH1A1RAB9AALOX12
SCHEMBL7054241 0.83 MEN1 (0.47) MEN1KMT2AALDH1A1RAB9AALOX12
SCHEMBL7053860 0.83 KMT2A (0.47) MEN1KMT2AALDH1A1RAB9AALOX12
SCHEMBL6545781 0.83 MEN1 (0.46) MEN1KMT2AALDH1A1RAB9AALOX12
SCHEMBL7054234 0.83 MEN1 (0.46) MEN1KMT2AALDH1A1RAB9AALOX12
SCHEMBL7053858 0.82 MEN1 (0.43) MEN1KMT2AALDH1A1RAB9AALOX12
SCHEMBL6546039 0.82 MEN1 (0.43) MEN1KMT2AALDH1A1RAB9AALOX12
SCHEMBL7051477 0.81 KMT2A (0.45) MEN1KMT2AALDH1A1RAB9AALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1257265-B1 USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS BIOAGENCY AG (DE) 2004-01-21 EP disclosed
US-20030036532-A1 Use of 2-phenylene diamine derivatives for the treatment of infections JOMAA PHARMAKA GMBH (DE) 2003-02-20 US disclosed
EP-1257265-A2 USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS Jomaa Pharmaka GmbH (DE) 2002-11-20 EP disclosed
WO-2001062709-A2 USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS JOMAA PHARMAKA GMBH (DE) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030036532-A1 Use of 2-phenylene diamine derivatives for the treatment of infections HRH2, ASPH, NQO2 MEN1 3863/4885KMT2A 1743/4885ALDH1A1 1419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.